ANDA 205064, held by Hetero Labs Ltd V. Aripiprazole.
As of Nov 16, 2026, ANDA 205064 (Aripiprazole), held by Hetero Labs Ltd V, was first approved by FDA on Apr 28, 2015, with 5 approved supplements and 0 published complete response letters.
Aripiprazole oral tablets are indicated for the treatment of: Schizophrenia Treatment of Tourette’s Disorder Aripiprazole tablets are an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia Treatment of Tourette’s disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2015 | Original application | Approved | None posted |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Rx |
| May 28, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 28, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 28, 2020 | Supplement 4Manufacturing | Approved | None posted |
| May 28, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 28, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters